Skip to main content
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

Globe Newswire - Thu Feb 24, 2022

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –

– Multiple milestones and data readouts from KOMET-001 expected in 2022 –

Read more at globenewswire.com